George B McDonald, Ole J B Landsverk, Dermot P B McGovern, Anders Aasebø, Vemund Paulsen, Talin Haritunians, Henrik M Reims, Bernadette M McLaughlin, Timothy Zisman, Dalin Li, Elisabeth T M M Elholm, Frode L Jahnsen, George E Georges, Tobias Gedde-Dahl
BACKGROUND & AIMS: Durable remissions of Crohn's Disease (CD) have followed myeloablative conditioning therapy and allogeneic marrow transplantation. For patients with treatment-refractory disease, we used reduced-intensity conditioning to minimize toxicity, marrow from donors with low Polygenic Risk Scores for CD as cell sources, and protracted immune suppression to lower the risk of graft-versus-host disease (GVHD). Our aim was to achieve durable CD remissions while minimizing transplant-related complications...
January 15, 2024: Heliyon